Madrigal Pharmaceuticals, Inc. (MDGL) Stock Overview
Explore Madrigal Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Madrigal Pharmaceuticals, Inc. (MDGL)
Key Financials
Key Financials
Market Cap
11.7B
P/E Ratio
-39.52
EPS (TTM)
$-12.80
ROE
-0.57%
MDGL Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Madrigal Pharmaceuticals, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of MDGL on the NASDAQ shows an RSI of 45.58, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $562.71 for the NASDAQ listing.
Key metrics behind Madrigal Pharmaceuticals, Inc.'s NASDAQ-traded stock include a P/E ratio of -39.52 and a market capitalization of 11.7B. Combined with our AI analysis, these give both institutional and retail investors a clear view of MDGL on the NASDAQ.